Receive The Newest Study Notifications

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological and neuropsychiatric diseases, today announced that the first patient has been...

Phase I results provide additional clinical activity data for Bicycles Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the successful completion of...

– Stem cell-derived islets successfully reduce insulin requirements in diabetic non-human primates – – Novel device successfully protects stem cell-derived islets in pigs without immunosuppression – – Company plans to initiate two clinical trials in 2020 – Semma...

A more effective seasonal flu vaccine is about to be tested in the US A more effective seasonal flu vaccine is about to be tested in clinical trials across the US. The flu shot was working well early in the season with effectiveness around 47% in February. But this...

Phase 2 trial will enroll approximately 30 patients and evaluate both safety and efficacy - Ziopharm Oncology, Inc. (“Ziopharm” or “the Company”) (Nasdaq:ZIOP) today announced the initiation of a phase 2 clinical trial evaluating Controlled IL-12 (Ad-RTS-hIL-12 plus...

Hope Pharmaceuticals today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) approved a clinical trial application for medical centers in the United Kingdom to participate in the international investigational clinical study that is...

Verrica Pharmaceuticals Inc. (Verrica) (Nasdaq: VRCA), a medical dermatology company committed to the development and commercialization of novel treatments that provide meaningful benefit for people living with skin diseases, today announced that the first patient has...

-vTv Therapeutics Inc. (Nasdaq: VTVT) announced today that the first patient has been screened for the phase 2 proof of concept study evaluating the safety and efficacy of azeliragon in patients with mild Alzheimer's disease and type 2 diabetes. “With positive results...

Ovid Therapeutics Inc. (NASDAQ: OVID), today announced that following a Type C Meeting with the U.S. Food and Drug Administration(FDA), it has initiated the pivotal Phase 3 NEPTUNE trial with OV101, a novel delta (δ)-selective GABAA receptor agonist, in Angelman...

On track with U.S. Phase 3 CHIASMA OPTIMAL trial; data now expected by mid-Q3 2019 Target enrollment completed in ongoing Phase 3 MPOWERED™ trial; data expected in 2H 2020 WALTHAM, Mass., June 27, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage...

– Faron Pharmaceuticals Oy (AIM: FARN), the clinical stage biopharmaceutical company, today announces interim results from the Phase II INFORAAA study, which examined the effect of Traumakine on mortality (predominantly for Multi-Organ Failure, MOF) and...

51% of subjects in Cohort 2 achieved complete clearance of all treatable warts VP-102 was well-tolerated with no serious adverse events reported Common warts affect approximately 22 million people in the United States Based on positive outcome, Verrica to request an...

-- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) today announced the completion of target enrollment of 198 participants for its pivotal Phase 3 registration trial ("REVEAL 1") of VGX-3100, a novel DNA-based immunotherapy being tested to treat cervical dysplasia caused...

The pharmaceutical company is on track to release topline results from its Phase 1 trials in December 2019 and Phase 2 trials in January 2020 Phase 3 trials of lead drug CaPre are currently underway Acasti Pharma Inc (NASDAQ:ACST) (CVE:ACST) noted a number of...

Study evaluating Oral KORSUVA (CR845/difelikefalin) for the treatment of pruritus in patients with primary biliary cholangitis (PBC) Oral KORSUVA is also the subject of a separate, ongoing Phase 2 trial for the treatment of pruritus in stage III-V chronic kidney...

 Zenith Epigenetics Ltd. (“Zenith” or the “Company”), a wholly-owned subsidiary of Zenith Capital Corp., announced today that it has dosed the first patient in a Phase 1b/2 clinical trial undertaken in collaboration with Pfizer Inc. (“Pfizer”). The trial will evaluate...

First oral microbiome biologic drug candidate from Assembly’s novel microbiome platform to enter clinical trials in patients ABI-M201 utilizes Assembly’s proprietary and patented Gemicel® capsule-in-capsule delivery system for targeted delivery into the GI tract SAN...

-- Yisheng Biopharma Co., Ltd. ("Yisheng Biopharma"), a biopharmaceutical company focusing on research, development, manufacturing, sales and marketing of immunological biologics and vaccines, announced that it has received Investigational New Drug (IND) clearance...

Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTCQB: HMTXF) is pleased to announce that it has enrolled a total of forty (40) patients in its continuing Phase II Clinical Trial for critical limb ischemia (“CLI”) to-date. As previously announced,...

Global study designed to assess the efficacy and safety of suvodirsen in DMD patients amenable to exon 51 skipping Results intended to support regulatory approvals globally Wave Life Sciences Ltd. (WVE), a clinical-stage genetic medicines company committed to...